within Pharmacolibrary.Drugs.ATC.C;

model C10AD52
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.7,
    Cl             = 0.0002666666666666667,
    adminDuration  = 600,
    adminMass      = 1000 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.00037,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.02,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>C10AD52</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Nicotinic acid, also known as niacin, is a lipid-lowering agent used in combination with other agents (such as statins or other lipid-modifying agents). It has historically been employed for the treatment of dyslipidemia by reducing total cholesterol, low-density lipoprotein (LDL), and triglycerides, while increasing high-density lipoprotein (HDL). The use of nicotinic acid combinations has declined in recent years due to unfavorable side effect profiles and lack of outcome benefits shown in recent trials. Approval status for these combinations varies by country, and some combinations have been withdrawn.</p><h4>Pharmacokinetics</h4><p>No specific published pharmacokinetic parameters for nicotinic acid, combinations (ATC C10AD52) in humans are available. The following values are rough estimates based on known pharmacokinetics of oral nicotinic acid in adults; parameters may vary significantly when combined with other agents.</p><h4>References</h4><ol><li><p> (2005). Final report of the safety assessment of niacinamide and niacin. <i>International journal of toxicology</i> 24 Suppl 5 1–31. DOI:<a href=&quot;https://doi.org/10.1080/10915810500434183&quot;>10.1080/10915810500434183</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/16596767/&quot;>https://pubmed.ncbi.nlm.nih.gov/16596767</a></p></li><li><p>McCormack, PL, &amp; Keating, GM (2005). Prolonged-release nicotinic acid: a review of its use in the treatment of dyslipidaemia. <i>Drugs</i> 65(18) 2719–2740. DOI:<a href=&quot;https://doi.org/10.2165/00003495-200565180-00014&quot;>10.2165/00003495-200565180-00014</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/16392885/&quot;>https://pubmed.ncbi.nlm.nih.gov/16392885</a></p></li><li><p>Heath, MS, et al., &amp; Feldman, SR (2018). Pharmacokinetics of tazarotene and acitretin in psoriasis. <i>Expert opinion on drug metabolism &amp; toxicology</i> 14(9) 919–927. DOI:<a href=&quot;https://doi.org/10.1080/17425255.2018.1515198&quot;>10.1080/17425255.2018.1515198</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/30134735/&quot;>https://pubmed.ncbi.nlm.nih.gov/30134735</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end C10AD52;
